SREBF1 and fatty liver disease: The hepatic overexpression of Dgat2, which catalyzes the final step of triglyceride synthesis, led to hepatic steatosis in mice [63], and liver-specific disruption of Pparγ or Srebf1 protected mice against hepatic steatosis [64].